Filing Flows › Aktis Oncology (AKTS) › Q2 2026
Aktis Oncology (AKTS) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Aktis Oncology (AKTS) reported revenue of $3.4M for the second quarter 2026 (Q2 2026), +111% from a year earlier and +5% from the quarter before. Operating margin was -854.0%, net loss $24.1M (713.5% of revenue).
Aktis Oncology, Q2 2026: revenue $3.4M (+111% year over year), operating margin -854.0%, net loss $24.1M, operating cash flow −$20.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.4M | +5% | +111% |
| Operating profit | −$28.9M | — | — |
| Net earnings | −$24.1M | — | — |
| Operating cash flow | −$20.6M | — | — |
What changed
Revenue was $3.4M in Q2 2026, up 111% year over year and up 5% from the previous quarter.
Operating costs exceeded revenue by $28.9M, an operating margin of -854.0%. Total costs grew 43% against revenue growth of 111%. The fastest-growing cost line was General & admin (+78%). The quarter ended with a net loss of $24.1M, wider than the previous quarter's $18.3M loss.
Operating cash flow was −$20.6M. Non-cash charges added back $879K of depreciation and amortization and $3.2M of share-based compensation. Capital expenditures of $1.3M exceeded it, leaving free cash flow of −$21.8M.
Questions
What was Aktis Oncology's revenue in the second quarter 2026?
Aktis Oncology (AKTS) reported revenue of $3.4M for the second quarter 2026 (Q2 2026), +111% from a year earlier and +5% from the quarter before.
Was Aktis Oncology profitable in the second quarter 2026?
Operating loss was $28.9M (-854.0% of revenue) and net loss $24.1M.
Source: Aktis Oncology 10-Q on SEC EDGAR.